[go: up one dir, main page]

PE20010486A1 - Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasa de matriz - Google Patents

Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasa de matriz

Info

Publication number
PE20010486A1
PE20010486A1 PE2000000833A PE0008332000A PE20010486A1 PE 20010486 A1 PE20010486 A1 PE 20010486A1 PE 2000000833 A PE2000000833 A PE 2000000833A PE 0008332000 A PE0008332000 A PE 0008332000A PE 20010486 A1 PE20010486 A1 PE 20010486A1
Authority
PE
Peru
Prior art keywords
alkyl
hydroxamic acid
inhibitors
acid compounds
sulfonylamine
Prior art date
Application number
PE2000000833A
Other languages
English (en)
Inventor
Christopher Alan Conrad
Patrick Michael O'brien
Drago Robert Sliskovic
Joseph Armand Picard
Daniel Fred Ortwine
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20010486A1 publication Critical patent/PE20010486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE ACIDO HIDROXAMICO DE FORMULA I, DONDE: X ES OH, NHOH; R1 ES EL GRUPO a, b, ENTRE OTROS; Y ES O, S, S(O)d, CH2, ENTRE OTROS; d ES 1-2; R2 ES H, ALQUILO C1-C4, BENCILO OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C4, ALCOXI C1-C4, F, Cl, Br, I, NH2, NO2, CN, CARBOXI, CO2R7; R7 ES H, ALQUILO C1-C4; R3 Y R4 SON ALQUILO C1-C20, CICLOALQUILO C3-C10, FENIL OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C4, ALCOXI C1-C4, HALO, NH2, NO2, CN, COOH, CO2R7, CF3, HETEROCICLICO C3-C19, ENTRE OTROS. SON COMPUESTOS PREFERIDOS ACIDO 1-(4`-BROMO-BIFENIL-4-SULFONILAMINO)-CICLOPENTAN0-CARBOXILICO; HIDROXAMIDA DE ACIDO 1-(4'-BROMO-BIFENIL-4-SULFONILAMINO)-CICLOPENTANO-CARBOXILICO, ACIDO 2-METIL-2-(6,7,8,9-TETRAHIDRO-DIBENZOFURANO-3-SULFONILAMINO)PROPIONICO, ENTRE OTROS. LOS COMPUESTOS DE ACIDO HIDROXAMICO DE FORMULA I SON INHIBIDORES DE LA METALOPROTEINASA DE MATRIZ POR LO QUE PUEDEN SER UTILES EN EL TRATAMIENTO DE ARTRITIS, ESCLEROSIS MULTIPLE, ATEREOESCLEROSIS, RESTENOSIS, OSTEOPOROSIS, INFLAMACION, DOLOR, ANEURISMA AORTICA, CARDIOPATIA, ULCERA DE CORNEA, CANCER
PE2000000833A 1999-08-18 2000-08-17 Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasa de matriz PE20010486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14966099P 1999-08-18 1999-08-18

Publications (1)

Publication Number Publication Date
PE20010486A1 true PE20010486A1 (es) 2001-04-20

Family

ID=22531286

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000833A PE20010486A1 (es) 1999-08-18 2000-08-17 Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasa de matriz

Country Status (18)

Country Link
US (1) US6677355B1 (es)
EP (1) EP1210326B1 (es)
JP (1) JP2003507362A (es)
AR (1) AR030160A1 (es)
AT (1) ATE260251T1 (es)
AU (1) AU6764400A (es)
BR (1) BR0013390A (es)
CA (1) CA2378332A1 (es)
CO (1) CO5300407A1 (es)
DE (1) DE60008548T2 (es)
DK (1) DK1210326T3 (es)
ES (1) ES2216938T3 (es)
MX (1) MXPA01013324A (es)
PE (1) PE20010486A1 (es)
PT (1) PT1210326E (es)
TR (4) TR200202163T2 (es)
UY (1) UY26302A1 (es)
WO (1) WO2001012592A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
ES2349041T3 (es) 2004-07-16 2010-12-22 Schering Corporation Derivados de hidantoina para el tratamiento de trastornos inflamatorios.
US7504424B2 (en) * 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
AR059036A1 (es) * 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
SI2343286T1 (sl) 2006-10-28 2015-05-29 Methylgene Inc. Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze
AR066412A1 (es) * 2007-05-04 2009-08-19 Wyeth Corp Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad.
AR073307A1 (es) 2008-09-24 2010-10-28 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
TW201024303A (en) 2008-09-24 2010-07-01 Schering Corp Compounds for the treatment of inflammatory disorders
WO2010054279A1 (en) 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders
US8569336B2 (en) 2008-11-10 2013-10-29 Ling Tong Compounds for the treatment of inflammatory disorders
KR20110096566A (ko) * 2008-12-05 2011-08-30 인터메드 디스커버리 게엠베하 Ｈｉｆ-1 단백질 축적의 억제제
JP2022512584A (ja) 2018-10-04 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 角皮症を処置するためのｅｇｆｒインヒビター
CN113336670B (zh) * 2021-05-28 2023-06-02 河南大学 一种轴手性芴胺-苯酚类衍生物及其制备方法
KR102701383B1 (ko) 2022-11-11 2024-09-04 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
PL334846A1 (en) * 1997-01-23 2000-03-27 Hoffmann La Roche Sulphamidic inhibitors of metaloproteases
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
AU730248B2 (en) * 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives

Also Published As

Publication number Publication date
JP2003507362A (ja) 2003-02-25
TR200202163T2 (tr) 2002-11-21
PT1210326E (pt) 2004-07-30
CO5300407A1 (es) 2003-07-31
US6677355B1 (en) 2004-01-13
BR0013390A (pt) 2002-04-30
AU6764400A (en) 2001-03-13
DK1210326T3 (da) 2004-06-21
WO2001012592A3 (en) 2001-07-05
EP1210326B1 (en) 2004-02-25
AR030160A1 (es) 2003-08-13
EP1210326A2 (en) 2002-06-05
TR200200410T2 (tr) 2002-06-21
TR200202211T2 (tr) 2002-11-21
ES2216938T3 (es) 2004-11-01
MXPA01013324A (es) 2002-07-02
CA2378332A1 (en) 2001-02-22
DE60008548D1 (de) 2004-04-01
DE60008548T2 (de) 2004-08-05
UY26302A1 (es) 2000-10-31
TR200202164T2 (tr) 2002-11-21
WO2001012592A2 (en) 2001-02-22
ATE260251T1 (de) 2004-03-15

Similar Documents

Publication Publication Date Title
PE20010486A1 (es) Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasa de matriz
PE97999A1 (es) Derivados de 4-bromo o 4-yodo fenilamino acido benzhidroxamico
ATE63553T1 (de) Chinazolindione und pyridopyrimidindione.
PE20010545A1 (es) Uso de una composicion de inhibidores de mek para el tratamiento del dolor cronico
PE98099A1 (es) Derivados de 2-(4-bromo o 4-yodo fenilamino) acido benzoico
BR9907962A (pt) Composição farmacêntica, composto, e, processo para preparar o mesmo
PE2799A1 (es) Lactamas e imidas heterociclicas de aralquilo y aralquilideno
ATE185558T1 (de) Prostaglandin-synthase hemmer
CO5200839A1 (es) Nuevos compuestos
ES2130079A1 (es) Resolucion de aminas
PE10997A1 (es) NUEVOS DERIVADOS DE [3-(4-FENILPIPERACIN-1-i1)PROPILAMINO]-PIRIDINA, PIRIMIDINA Y BENCENO COMO ANTAGONISTAS DE a1-ADRENOCEPTORES, SUS EMPLEOS COMO AGENTES TERAPEUTICOS Y LOS METODOS PARA SU PREPARACION
ES2187025T3 (es) Nuevos agentes quelantes de hierro (iii) activos via oral.
ES480151A1 (es) Un procedimiento para la obtencion de nuevos azacicloalcanos.
BR9806321A (pt) Processo e composição para inibir a polimerização durante a produção anaeróbica de estireno.
CO5720995A2 (es) Compuesto novedoso
CO5070675A1 (es) Pirroles sustituidos
IT1271026B (it) Derivati dell'acido b-amminopropionico ad attivita' fungicida
ES2166972T3 (es) Procedimiento para preparar alfa-hidroxiacidos libres a partir de sus sales amonicas.
DE50102101D1 (de) Verfahren zur Herstellung von 2-Arylbenzimidazolsulfonsäuren
PE28199A1 (es) Nuevos inhibidores de farnesil transferasa, su preparacion, las composiciones farmaceuticas que las contienen y su utilizacion para la preparacion de medicamentos
DE69808099D1 (de) Substituierte 6-alkylphenanthridine
BR9807761A (pt) oscópicos de l(-)carnitina
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
EA199800189A1 (ru) Оптически активное производное фенилпиримидина в качестве анальгетика
EA199600007A2 (ru) Новые трициклические производные, способ их получения, способы получения оптически активных или рацемических колхицина и тиоколхицина, их аналогов или производных с использованием трициклических соединений и промежуточные продукты синтеза

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed